Hepatology News and Research RSS Feed - Hepatology News and Research

Hepatology is the branch of medicine that incorporates study of liver, gallbladder, biliary tree and pancreas as well as management of their disorders.
Risk prediction model can help target hepatitis C treatment to patients with most urgent need

Risk prediction model can help target hepatitis C treatment to patients with most urgent need

A team of researchers at the University of Michigan Health System has developed a risk prediction model that helps identify which hepatitis C patients have the most urgent need for new anti-viral drugs. [More]
CLDF collaborates with Walgreens to offer free rapid HCV testing

CLDF collaborates with Walgreens to offer free rapid HCV testing

The Chronic Liver Disease Foundation announced today that it's collaborating with Walgreens to offer free hepatitis C (HCV) testing with the OraQuick HCV Rapid Test at more than 60 Walgreens retail pharmacies in 12 major cities throughout the country. [More]
Current menopausal hormone therapy users at increased risk of experiencing GI bleeding

Current menopausal hormone therapy users at increased risk of experiencing GI bleeding

Current users of menopausal hormone therapy (MHT) are more than twice as likely than non-users to develop lower gastrointestinal bleeding and ischemic colitis, especially if they use the therapy for longer durations, according to a study at Digestive Disease Week 2015. [More]
Patients want to take more active role in decision-making process, study finds

Patients want to take more active role in decision-making process, study finds

Patients faced with a choice of surgical options want to engage their physicians and take a more active role in decision-making, according to a study (abstract 567) released at Digestive Disease Week 2015. [More]
Live, multi-strain probiotic drink may benefit people with ulcerative colitis

Live, multi-strain probiotic drink may benefit people with ulcerative colitis

People with ulcerative colitis may benefit from taking the live, multi-strain probiotic drink, Symprove, to reduce intestinal inflammation, according to the results of a new study presented today at Digestive Disease Week 2015. [More]
Investing in new hepatitis C therapies may have significant economic impact

Investing in new hepatitis C therapies may have significant economic impact

While a new generation of safer, more effective oral medications to treat hepatitis C patients may cost tens of thousands of dollars for a 12-week regiment, investing in these new therapies could generate savings estimated at more than $3.2 billion annually in the U.S. and five European countries, according to a new study (abstract 228) released today at Digestive Disease Week® (DDW) 2015. [More]
Simple blood test could help predict effectiveness of interferon-based therapy in HCV-infected patients

Simple blood test could help predict effectiveness of interferon-based therapy in HCV-infected patients

A simple blood test can be used to predict which chronic hepatitis C patients will respond to interferon-based therapy, according to a report in the May issue of Cellular and Molecular Gastroenterology and Hepatology, the basic science journal of the American Gastroenterological Association. [More]
Exalenz Bioscience investigates clinical utility of BreathID test to diagnose NASH

Exalenz Bioscience investigates clinical utility of BreathID test to diagnose NASH

Exalenz Bioscience, a leader in developing and marketing of non-invasive medical devices for diagnosing and monitoring a range of gastrointestinal and liver diseases, today announced the initiation of a clinical study evaluating the potential of its BreathID test to diagnose nonalcoholic steatohepatitis (NASH). [More]
International study finds that two-week diet swap for African-Americans may lower colon cancer risk

International study finds that two-week diet swap for African-Americans may lower colon cancer risk

African-Americans and Africans who swapped their typical diets for just two weeks similarly exchanged their respective risks of colon cancer as reflected by alterations of their gut bacteria, according to an international study led by researchers at the University of Pittsburgh School of Medicine published online today in Nature Communications. [More]
Combination therapy effective in HCV patients with advanced cirrhosis and post-transplant recurrence

Combination therapy effective in HCV patients with advanced cirrhosis and post-transplant recurrence

Phase 3 results presented today at The International Liver Congress 2015 show that a combination of daclatasvir (DCV), sofosbuvir (SOF) and ribavirin (RBV) for 12 weeks was effective and well tolerated amongst patients with hepatitis C virus (HCV) infection with advanced cirrhosis and post-transplant recurrence. [More]
Sofosbuvir-based regimens effective in HIV-HCV co-infected, cirrhotic patients

Sofosbuvir-based regimens effective in HIV-HCV co-infected, cirrhotic patients

A new study revealed today at The International Liver Congress 2015 shows that sofosbuvir (SOF)-based regimens are effective and well tolerated in hepatitis C and HIV co-infected, cirrhotic patients. Sustained virologic response at 4 weeks (SVR4) was observed in 98% of patients and in 95% at 12 weeks (SVR12). [More]
Sofosbuvir in combination with ribavirin/peginterferon achieves highest SVR rates in GT-3 HCV patients

Sofosbuvir in combination with ribavirin/peginterferon achieves highest SVR rates in GT-3 HCV patients

Results presented today at The International Liver Congress 2015 demonstrate that hepatitis C (HCV)-infected genotype-3 (GT-3) patients, with and without cirrhosis, receiving 24 weeks of sofosbuvir (SOF) in combination with ribavirin (RBV) and peginterferon (PEG) achieved the highest sustained virologic response rates at 12 weeks (SVR12), observed in a Phase 3 study, to date. [More]
Combination treatment effective for HCV genotype-1 mono-infected patients

Combination treatment effective for HCV genotype-1 mono-infected patients

Results presented today at The International Liver Congress 2015 show that the sofosbuvir (SOF)/daclatasvir (DCV) treatment combination is effective amongst hepatitis C virus (HCV) genotype-1 mono-infected patients. These results are significant because whilst other combinations have been widely reported on, there have been few data until now regarding the use of SOF/DCV combination in real world situations. [More]
Pocket-sized ultrasound device reduce need for further testing in inpatient and outpatient settings

Pocket-sized ultrasound device reduce need for further testing in inpatient and outpatient settings

Results from a study presented today at The International Liver Congress 2015 demonstrate that the use of a pocket-sized ultrasound device (PUD) helps to reduce the need for further testing in both the inpatient and outpatient setting. [More]
New data supports use DAAs in patients with HCV recurrence following liver transplantation

New data supports use DAAs in patients with HCV recurrence following liver transplantation

New data presented today at The International Liver Congress 2015, supports the use of sofosbuvir (SOF)- and daclatasvir (DCV)-based regimens in patients with recurrence of the hepatitis C virus (HCV) following liver transplantation (LT). [More]
Systematic review shows hepatitis B and C testing lacking in many European countries

Systematic review shows hepatitis B and C testing lacking in many European countries

The apparent dearth of research on hepatitis B and C testing in many European countries could be hampering efforts to identify infected individuals, according to results from a comprehensive review of 136 studies presented today at The International Liver Congress 2015. [More]
Occurrence of advanced liver fibrosis similar for patients with HCV infection

Occurrence of advanced liver fibrosis similar for patients with HCV infection

Study results presented today at The International Liver Congress 2015 show that the occurrence of advanced liver fibrosis is similar for patients infected with the hepatitis C virus (HCV), whether or not they have been diagnosed. [More]
New study shows significant influence of daily drinking on cirrhosis

New study shows significant influence of daily drinking on cirrhosis

According to the World Health Organization, excessive alcohol drinking is the most common cause of cirrhosis worldwide. A new worldwide study presented at The International Liver Congress 2015 has shown the significant influence of daily drinking on this disease burden. [More]
AUDs have negative prognostic outcome with higher mortality risks in patients with HCV infection

AUDs have negative prognostic outcome with higher mortality risks in patients with HCV infection

Results presented today at The International Liver Congress 2015, show that alcohol use disorders (AUD) have a serious, negative prognostic outcome with higher mortality risks in the general population and patients with hepatitis C virus (HCV) infection in particular. [More]
AbbVie's all-oral, interferon-free therapy granted FDA priority review for treatment of GT4 HCV infection

AbbVie's all-oral, interferon-free therapy granted FDA priority review for treatment of GT4 HCV infection

AbbVie has announced that the U.S. Food and Drug Administration has accepted its New Drug Application (NDA) and granted priority review for the company's, all-oral, interferon-free, two direct-acting antiviral treatment of ombitasvir, paritaprevir, ritonavir (OBV/PTV/r), with ribavirin (RBV). [More]
Advertisement
Advertisement